Northwest Biotherapeutics (OTCMKTS:NWBO – Get Free Report) posted its earnings results on Friday. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, Zacks reports.
Northwest Biotherapeutics Stock Up 1.1%
Shares of NWBO stock traded up $0.00 during trading on Friday, hitting $0.19. The company had a trading volume of 1,431,468 shares, compared to its average volume of 3,070,253. The stock’s 50-day moving average is $0.18 and its two-hundred day moving average is $0.21. The stock has a market capitalization of $324.11 million, a price-to-earnings ratio of -0.01 and a beta of -0.60. Northwest Biotherapeutics has a 52 week low of $0.14 and a 52 week high of $0.37.
About Northwest Biotherapeutics
Northwest Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of cancer. The company’s proprietary platform harnesses patient-derived dendritic cells to present tumor-specific antigens and stimulate a targeted immune response. By tailoring each vaccine to the individual patient’s tumor profile, the approach aims to improve outcomes and reduce off-target toxicity associated with conventional therapies.
The company’s lead candidate, DCVax®-L, is designed for patients with newly diagnosed or recurrent glioblastoma multiforme (GBM) and has advanced through a global Phase III clinical trial.
Read More
- Five stocks we like better than Northwest Biotherapeutics
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
